Impact of bivaluridin and Genous stent in patients with acute myeloid leukemia undergoing emergency percutaneous coronary angioplasty for acute coronary syndrome.

Hematological disorders are considered risk factors for acute and late complications in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In particular, thrombocytopenia (TP) is associated with a higher risk for bleeding in patients with ACS treated with antithrombotic therapies1 and has been shown to be a predictor of in-hospital mortality in patients undergoing PCI. In acute myeloid leukemia (AML), replacement of normal bone marrow with leukemic cells causes anemia, TP, and abnormal white blood cells count.